



Immunomic Therapeutics, Inc.

Press Release

October 2, 2006

Immunomic Therapeutics, Inc.
9290 Gaither Road
Gaithersburg, MD 20877

Ph: 240-731-5232
Fax: 240-597-4061
info@immunomictherapeutics.com
www.immunomix.com

FOR IMMEDIATE RELEASE: October 2, 2006 (Gaithersburg, MD)

Immunomic Therapeutic Announces Exclusive License Agreement with Johns Hopkins University for LAMP Technology

Gaithersburg, MD, October 2, 2006 /-- Immunomic Therapeutics, Inc. (ITI, www.immunomictherapeutics.com) announced today that it has acquired the worldwide exclusive rights to the LAMP Vaccine technology from Johns Hopkins University.

ITI represents a collaborative effort between JHU, the inventors including Dr. J. Thomas August and Capital Genomix, Inc., a Maryland based biotechnology company to develop and commercialize vaccines for cancer, infectious diseases and other targets based on the LAMP technology covered under issued U.S. and foreign patents.

Dr. Bill Hearl, president and CEO of ITI said, "This license agreement forms the core of the intellectual property of Immunomics and creates an opportunity to build many collaborative relationships with laboratories already active in LAMP research. We are very excited to get started." He said he expects the Company to complete its first sub-licensing deal before the end of 2006.

About Immunomic Therapeutics

Immunomic Therapeutics, Inc. ("ITI") is a privately held biotechnology company headquartered in Gaithersburg, Maryland that is commercializing a portfolio of clinical applications based on "LAMP" vaccine technology. ITI offers access to LAMP – based vectors and novel vaccine design through license and collaborative research agreements. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com.

This press release may contain forward looking statements regarding, among other matters, the Company's future prospects. Forward looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of ITI's technologies, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Future results of the Company will depend on a variety of factors, including the timing of significant orders, the ability of the Company to timely manufacture and deliver ordered products, the ability of the Company to bring new systems to market, the timing of new product releases by the Company's competitors and other competitive factors.

CONTACT:

Immunomic Therapeutics, Inc.
Bill Hearl, Ph.D., President & CEO
240-731-5232
bhearl@immunomictherapeutics.com